Format
Sort by

Send to

Choose Destination

Selected items

Items: 5

1.

Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients.

Wiench M, Wygoda Z, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Krawczyk Z, Jarzab B.

J Clin Oncol. 2001 Mar 1;19(5):1374-80.

PMID:
11230481
2.

Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.

Colombo-Benkmann M, Li Z, Riemann B, Hengst K, Herbst H, Keuser R, Gross U, Rondot S, Raue F, Senninger N, Pützer BM, Frank-Raue K.

Eur J Endocrinol. 2008 Jun;158(6):811-6. doi: 10.1530/EJE-07-0817. Epub 2008 Mar 5.

PMID:
18322301
3.

Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.

Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I, Schott M, Gabbert HE, Valimäki M, Preuss SF, Hasse-Lazar K, Waligorski D, Robledo M, Januszewicz A, Eng C, Neumann HP.

J Clin Endocrinol Metab. 2010 Jan;95(1):308-13. doi: 10.1210/jc.2009-1728. Epub 2009 Nov 11.

4.
5.

In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.

Prazeres H, Couto JP, Rodrigues F, Vinagre J, Torres J, Trovisco V, Martins TC, Sobrinho-Simões M, Soares P.

Endocr Relat Cancer. 2011 Jul 1;18(4):401-12. doi: 10.1530/ERC-10-0258. Print 2011 Aug. Erratum in: Endocr Relat Cancer. 2016 Dec;23 (12 ):X1.

PMID:
21551259

Supplemental Content

Support Center